171 related articles for article (PubMed ID: 32233081)
1. Use of psycho-oncological services by prostate cancer patients: A multilevel analysis.
Breidenbach C; Roth R; Ansmann L; Wesselmann S; Dieng S; Carl EG; Feick G; Oesterle A; Bach P; Beyer B; Borowitz R; Erdmann J; Kunath F; Oostdam SJ; Tsaur I; Zengerling F; Kowalski C
Cancer Med; 2020 Jun; 9(11):3680-3690. PubMed ID: 32233081
[TBL] [Abstract][Full Text] [Related]
2. Predictors for the utilization of social service counseling by prostate cancer patients.
Breidenbach C; Ansmann L; Sibert NT; Wesselmann S; Dieng S; Carl EG; Feick G; Stoklossa C; Taubert A; Pomery A; Beyer B; Blana A; Brock M; Distler F; Enge M; Gaber AA; Gilfrich C; Hinkel A; Kaftan B; Knoll T; Kunath F; Oostdam SJ; Peters I; Polat B; Schrodi V; Zengerling F; Kowalski C
Support Care Cancer; 2022 Mar; 30(3):2327-2339. PubMed ID: 34738162
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
4. Oncologist recommendation matters!-Predictors of psycho-oncological service uptake in oncology outpatients.
Frey Nascimento A; Tondorf T; Rothschild SI; Koller MT; Rochlitz C; Kiss A; Schaefert RM; Meinlschmidt GP; Hunziker S; Gaab J; Zwahlen D
Psychooncology; 2019 Feb; 28(2):351-357. PubMed ID: 30466146
[TBL] [Abstract][Full Text] [Related]
5. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
6. Radical prostatectomy or watchful waiting in early prostate cancer.
Bill-Axelson A; Holmberg L; Garmo H; Rider JR; Taari K; Busch C; Nordling S; Häggman M; Andersson SO; Spångberg A; Andrén O; Palmgren J; Steineck G; Adami HO; Johansson JE
N Engl J Med; 2014 Mar; 370(10):932-42. PubMed ID: 24597866
[TBL] [Abstract][Full Text] [Related]
7. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
8. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
9. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
Berge V; Thompson T; Blackman D
Scand J Urol Nephrol; 2007; 41(3):198-203. PubMed ID: 17469027
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
Ansmann L; Winter N; Ernstmann N; Heidenreich A; Weissbach L; Herden J
BJU Int; 2018 Sep; 122(3):401-410. PubMed ID: 29603553
[TBL] [Abstract][Full Text] [Related]
13. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
14. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
[TBL] [Abstract][Full Text] [Related]
15. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
16. Satisfaction with Care Among Men with Localised Prostate Cancer: A Nationwide Population-based Study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
Eur Urol Oncol; 2018 May; 1(1):37-45. PubMed ID: 31100227
[TBL] [Abstract][Full Text] [Related]
17. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
[TBL] [Abstract][Full Text] [Related]
18. Impact on quality of life 3 years after diagnosis of prostate cancer patients below 75 at diagnosis: an observational case-control study.
Houédé N; Rébillard X; Bouvet S; Kabani S; Fabbro-Peray P; Trétarre B; Ménégaux F
BMC Cancer; 2020 Aug; 20(1):757. PubMed ID: 32787797
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns for older veterans with localized prostate cancer.
Hoffman RM; Shi Y; Freedland SJ; Keating NL; Walter LC
Cancer Epidemiol; 2015 Oct; 39(5):769-77. PubMed ID: 26228494
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
